Investor Relations
Aug 07, 2018
OPKO Health Reports Second Quarter 2018 Financial Results MORE >>
Aug 03, 2018
OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children MORE >>
Aug 02, 2018
OPKO Health to Announce Second Quarter 2018 Financial Results on August 7, 2018 MORE >>
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>

SEC Filing Details

Document Details

Filing Date
Apr 30, 2018
Document Date
Jun 21, 2018
Form Description
Official notification to shareholders of matters to be brought to a vote ("Proxy")
Filing Group
Proxy Filings
OPKO Health, Inc.